Francis W. Spierto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Francis W. Spierto has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
F Gardner
Division of Laboratory Sciences, National Center for Environmental Health Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
1 shared publicationF. Hugh Gardner
Division of Environmental Health Laboratory Sciences, Center for Environmental Health, Centers for Disease Control, Public Health Services, U.S. Department of Health and Human Services , Atlanta, Georgia 30333
1 shared publicationMary K. Powell
Division of Environmental Health Laboratory Sciences, Center for Environmental Health, Centers for Disease Control, Public Health Services, U.S. Department of Health and Human Services , Atlanta, Georgia 30333
1 shared publicationRobert Vogt
Division of Environmental Health Laboratory Sciences, Center for Environmental Health, Centers for Disease Control, Public Health Services, U.S. Department of Health and Human Services , Atlanta, Georgia 30333
1 shared publicationS.J Smith
Division of Laboratory Sciences, National Center for Environmental Health Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
1 shared publicationW. Harry Hannon
Division of Environmental Health Laboratory Sciences, Center for Environmental Health, Centers for Disease Control, Public Health Services, U.S. Department of Health and Human Services , Atlanta, Georgia 30333
1 shared publication
Latest Publications
- 1 January 1987
- Published by Oxford University Press (OUP) in Journal of Analytical Toxicology
- Vol. 11 (1) , 31-35
Development and Evaluation of a Microtiter Plate Enzyme Immunoassay for Antibodies to 3,3′-Dichlorobenzidine
The authors obtained and evaluated antisera from rabbits injected with a derivative of a potent bladder carcinogen, dichlorobenzidine (DCB), conjugated to bovine serum albumin (BSA). A 14C-radioimmunoassay (RIA) was able to detect the presence of DCB antibodies, but its relative insensitivity led to the development of a more sensitive enzyme immunoassay (EIA). The EIA test was a “sandwich” method in which a second antibody, labeled with an enzyme (horseradish peroxidase), was used to measure antibody binding to transferrin (Tf)-conjugated DCB immobilized on a microtiter plate. Antibody titers measured by RIA were approximately 1:40; when measured by EIA, they were approximately 1:40,000. Antibody specificity was assessed by comparing the antibody binding activities of DCB, BSA, Tf, BSA-conjugated to DCB, and a number of N-substituted aromatic compounds that included benzidine (Bz). Among the compounds tested, the rabbit antiserum reacted only with DCB and the carrier protein, BSA. Moreover, antibody binding activity to Tf-conjugated DCB was significantly inhibited by unconjugated DCB concentrations between 30 and 500 ng/mL. The precision of antibody binding activities as a function of DCB concentration (expressed by the CV) ranged from 9% for low (30 ng/mL) DCB levels to 12% for higher (500 ng/mL) levels. This evaluation suggests that the antiserum obtained would be appropriate for detecting DCB levels at the ng/mL level.
- 1 January 1987
- Published by Oxford University Press (OUP) in Journal of Analytical Toxicology
- Vol. 11 (1) , 31-35
Development and Evaluation of a Microtiter Plate Enzyme Immunoassay for Antibodies to 3,3′-Dichlorobenzidine
The authors obtained and evaluated antisera from rabbits injected with a derivative of a potent bladder carcinogen, dichlorobenzidine (DCB), conjugated to bovine serum albumin (BSA). A 14C-radioimmunoassay (RIA) was able to detect the presence of DCB antibodies, but its relative insensitivity led to the development of a more sensitive enzyme immunoassay (EIA). The EIA test was a “sandwich” method in which a second antibody, labeled with an enzyme (horseradish peroxidase), was used to measure antibody binding to transferrin (Tf)-conjugated DCB immobilized on a microtiter plate. Antibody titers measured by RIA were approximately 1:40; when measured by EIA, they were approximately 1:40,000. Antibody specificity was assessed by comparing the antibody binding activities of DCB, BSA, Tf, BSA-conjugated to DCB, and a number of N-substituted aromatic compounds that included benzidine (Bz). Among the compounds tested, the rabbit antiserum reacted only with DCB and the carrier protein, BSA. Moreover, antibody binding activity to Tf-conjugated DCB was significantly inhibited by unconjugated DCB concentrations between 30 and 500 ng/mL. The precision of antibody binding activities as a function of DCB concentration (expressed by the CV) ranged from 9% for low (30 ng/mL) DCB levels to 12% for higher (500 ng/mL) levels. This evaluation suggests that the antiserum obtained would be appropriate for detecting DCB levels at the ng/mL level.